Nuvalent, Inc. Competitors
| Symbol | Company | Share Price | Market Cap | P/E Ratio | Employee Count | Revenue |
|---|---|---|---|---|---|---|
 ACLX
|
Arcellx, Inc. | $78.20 | $2.72 B | -49.3 | 130 | $110.32 M |
 ASND
|
Ascendis Pharma A/S | $142.68 | $7.77 B | -14.19 | 879 | $266.72 M |
 CERE
|
Cerevel Therapeutics Holdings, Inc. | $44.96 | $7.29 B | -14.66 | 355 | $0 |
 CGEM
|
Cullinan Oncology, Inc. | $16.32 | $1.29 B | -7.16 | 85 | $0 |
 DICE
|
DICE Therapeutics, Inc. | $47.55 | $2.27 B | -21.91 | 71 | $0 |
 GPCR
|
Structure Therapeutics Inc. | $43.08 | $2.47 B | -23.59 | 136 | $0 |
 KNSA
|
Kiniksa Pharmaceuticals, Ltd. | $24.45 | $1.35 B | 146.62 | 297 | $270.26 M |
 PCVX
|
Vaxcyte, Inc. | $111.39 | $7.72 B | -16.54 | 254 | $0 |
 REPL
|
Replimune Group, Inc. | $11.48 | $485.18 M | -2.44 | 331 | $0 |
 TVTX
|
Travere Therapeutics, Inc. | $15.23 | $542.80 M | -1.32 | 380 | $145.24 M |
 UTHR
|
United Therapeutics Corporation | $355.67 | $12.20 B | 13.02 | 1168 | $2.33 B |
 VRDN
|
Viridian Therapeutics, Inc. | $23.87 | $776.72 M | -2.71 | 94 | $314,000 |
 VTYX
|
Ventyx Biosciences, Inc. | $2.12 | $229.83 M | -1.01 | 73 | $0 |